Femasys (FEMY) Cash from Financing Activities (2020 - 2026)
Femasys (FEMY) posted Cash from Financing Activities of $342334.0 for Q1 2026, down 96.23% on a QoQ basis from $9.1 million in Q4 2025, and down 93.45% year-over-year from $5.2 million in Q1 2025.
Femasys (FEMY) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Femasys' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $342334.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 93.45% year-over-year to $342334.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.2 million (up 212.48% YoY) and the FY2025 annual result came in at $25.1 million, up 1139.74% from the prior year.
- Cash from Financing Activities was $342334.0 for Q1 2026 at Femasys, down from $9.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $16.1 million in Q4 2023 and bottomed at -$362039.0 in Q3 2022.
- A 5-year average of $2.9 million and a median of $824252.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 100.32% — and 2023, when it surged 19751.64%.
- Femasys' Cash from Financing Activities stood at -$81950.0 in 2022, then jumped by 19751.64% to $16.1 million in 2023, then tumbled by 93.63% to $1.0 million in 2024, then jumped by 785.15% to $9.1 million in 2025, then slumped by 96.23% to $342334.0 in 2026.
- Business Quant data shows FEMY's Cash from Financing Activities at $342334.0 in Q1 2026, $9.1 million in Q4 2025, and $7.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | -133.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -414.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | -13.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | -255.24 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -50.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | -48.13 Mn |
| 10 | Femasys | 17.46 Mn | 12.07 Mn | - | 342,334.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 342,334.00 |
| Mar 31, 2026 | 342,334.00 |
| Dec 31, 2025 | 9.08 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Jun 30, 2024 | 223,549.00 |
| Jun 30, 2024 | 223,549.00 |
| Mar 31, 2024 | 778,175.00 |
| Mar 31, 2024 | 778,175.00 |
| Dec 31, 2023 | 16.10 Mn |
| Dec 31, 2023 | 16.10 Mn |
| Sep 30, 2023 | 870,329.00 |
| Sep 30, 2023 | 870,329.00 |